Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer (Q33574315)

28 July 2017

title

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer (English)

1 reference

28 July 2017

Naoki Takahashi

1

1 reference

28 July 2017

Yasuhide Yamada

2

1 reference

28 July 2017

Hirokazu Taniguchi

3

1 reference

28 July 2017

Masaru Fukahori

4

1 reference

28 July 2017

Yusuke Sasaki

5

1 reference

28 July 2017

Hirokazu Shoji

6

1 reference

28 July 2017

Yoshitaka Honma

7

1 reference

28 July 2017

Satoru Iwasa

8

1 reference

28 July 2017

Atsuo Takashima

9

1 reference

28 July 2017

Ken Kato

10

1 reference

28 July 2017

Tetsuya Hamaguchi

11

1 reference

28 July 2017

Yasuhiro Shimada

12

1 reference

28 July 2017

publication date

29 April 2014

1 reference

28 July 2017

1 reference

28 July 2017

volume

7

1 reference

28 July 2017

page(s)

271

1 reference

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

NRAS mutation status is an independent prognostic factor in metastatic melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

28 July 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

PIK3CA mutation associates with improved outcome in breast cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Mutation of the PIK3CA oncogene in human cancers

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

BRAF mutation in thyroid cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Mutations of PIK3CA in gastric adenocarcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

High frequency of mutations of the PIK3CA gene in human cancers

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012089

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

BRAF and KRAS mutations in stomach cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

Novel therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-0500-7-271

BRAF and RAS mutations in human lung cancer and melanoma

21 January 2018

1 reference

12 December 2020

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

12 December 2020

Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability

1 reference

12 December 2020

PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-0500-7-271

1 reference

Dimensions Publication ID

28 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1756-0500-7-271

9 September 2019

1 reference

28 July 2017

1 reference